Weighing in: emergent diabetes mellitus and second-generation antipsychotics.
Of all the metabolic effects of some of the atypical second-generation antipsychotics, their potential to induce glucose dysregulation has induced a storm of controversy over the past several years. The numerous published epidemiologic studies are difficult to interpret due to the high background rate of type 2 diabetes mellitus in this population, the inherent problems with analysis of observational data, and the short duration of the available studies. A plan to monitor for weight gain, hypertriglyceridemia, glucose dysregulation, and other potential adverse metabolic effects resulting from antipsychotic treatment is critical.
Dufresne
Robert L
RL
Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI, USA. rdu3990u@postoffice.uri.edu
D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D009765:Obesity / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control; D015430:Weight Gain / Q000187:drug effects / Q000502:physiology